SCHEMBL3021340

SCHEMBL3021340

CC(C)(C)c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(Cl)cc(Cl)c4)cs3)CC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD11B1 P28845 3/20 0.35
TP53 P04637 1/20 0.34
HTR2A P28223 2/20 0.33
DNM1L O00429 2/20 0.33
EPHX2 P34913 1/20 0.33
GBA1 P04062 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2C P28335 1/20 0.33
KCNH2 Q12809 1/20 0.33
RAB9A P51151 1/20 0.32
CCR6 P51684 1/20 0.32
CNR2 P34972 1/20 0.32
KDM2B Q8NHM5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005733 0.95 HTR2A (0.35) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3011697 0.93 HSD11B1 (0.39) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3012528 0.91 DNM1L (0.37) MAPTSMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL3010926 0.90 MAPT (0.40) MAPTSMN1; SMN2LMNANPSR1HTR2A
SCHEMBL3014922 0.90 LMNA (0.37) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3006919 0.90 ALDH1A1 (0.35) MAPTSMN1; SMN2ALDH1A1HSD11B1HTR2A
SCHEMBL3015929 0.89 TRPV1 (0.36) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3013097 0.89 GBA1 (0.42) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3012703 0.89 HTR2A (0.41) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL3018999 0.88 EPHX2 (0.45) MAPTSMN1; SMN2ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.